|Articles|February 1, 2012
- Pharmaceutical Executive-02-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - February 2012
Brand of the Year : Abbott's Humira
Advertisement
Articles in this issue
over 14 years ago
How to Choose a Medical Animatorover 14 years ago
Money for Nothing, Patents for Free?over 14 years ago
Trying Trials at GC-2over 14 years ago
Prizing the Eye : Brent Saunders, CEO Bausch + Lombover 14 years ago
Brand Success: It's Not Serendipityover 14 years ago
Brazil Report: A Bold Player Bloomsover 14 years ago
Of Farms, Beaches … and Genericsover 14 years ago
FDA Social Media Guidelines: Irresponsible?over 14 years ago
Time to Appoint a 'Chief Patient Officer'?over 14 years ago
Japanese Knowledge Brought to BrazilAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy
2
The Pharma Patent Cliff Explained: What It Is and How Companies Navigate It
3
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
4
FDA Sends CRL to Cingulate for CTx-1301
5